The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
 
Carrie Ho
No Relationships to Disclose
 
Jonathan R. Fromm
No Relationships to Disclose
 
Min Fang
No Relationships to Disclose
 
Brian G. Till
Stock and Other Ownership Interests - Proteios Technology
Consulting or Advisory Role - MustangBio; Proteios Technology
Research Funding - Bristol-Myers Squibb/Celgene/Juno; MustangBio (Inst)
Patents, Royalties, Other Intellectual Property - Patent and royalties for a CD20-targeted chimeric antigen receptor from Mustang Bio
 
Mazyar Shadman
Employment - Bristol-Myers Squibb (I)
Consulting or Advisory Role - Abbvie; Adaptimmune; Adaptive Biotechnologies; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; Epizyme; Fate therapeutics; Genentech; Innate Pharma; Kite, a Gilead company; Lilly; MEI Pharma; MorphoSys; MustangBio; Pharmacyclics; Regeneron; Sound Biologics; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Genentech (Inst); Genmab (Inst); Merck (Inst); MustangBio (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst)
 
Andrew Cowan
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene/Juno; Cellectar; Doximity; Janssen; Sanofi; Secura Bio
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Harpoon therapeutics (Inst); Janssen (Inst); Nektar (Inst)
 
Ryan C. Lynch
Consulting or Advisory Role - Foresight Diagnostics; SeaGen
Research Funding - Bayer; Cyteir; Genentech; Incyte; RAPT Therapeutics; Seagen; TG Therapeutics
 
Vicky Wu
No Relationships to Disclose
 
Jenna M. Voutsinas
No Relationships to Disclose
 
Heather A. Rasmussen
No Relationships to Disclose
 
Katharine Blue
No Relationships to Disclose
 
Chaitra Shankar Ujjani
Honoraria - Abbvie; BeiGene; Genentech; incyte; Janssen; Lilly; Pharmacyclics
Consulting or Advisory Role - AstraZeneca; Atara Biotherapeutics; Epizyme
Research Funding - Abbvie (Inst); Adaptive Biotechnologies; AstraZeneca/MedImmune; Kite, a Gilead company; Lilly; Pharmacyclics (Inst)
 
Andrei R. Shustov
Employment - Seagen
 
Ryan Daniel Cassaday
Employment - Seagen (I)
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Kite, a Gilead company; Pfizer
Consulting or Advisory Role - Amgen; Jazz Pharmaceuticals; Kite/Gilead; Pfizer
Research Funding - Amgen (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Pfizer; SERVIER (Inst); Vanda Pharmaceuticals
Travel, Accommodations, Expenses - Kite, a Gilead company
Other Relationship - Autolus; Pepromene
 
Ajay K. Gopal
Honoraria - Actinium Pharmaceuticals; ADC Therapeutics; Amgen; Cellectar; Epizyme; Gilead Sciences; I-mab; Janssen Oncology; Kite/Gilead; Merck; morphosys; nurix; Pfizer; Seagen; Takeda; TG Therapeutics
Consulting or Advisory Role - Cellectar; Gilead Sciences; I-Mab; Incyte; Janssen Oncology; Kite/Gilead; Millennium; morphosys; nurix; Pfizer; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); I-Mab (Inst); IgM (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst)
 
Stephen Douglas Smith
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Coherus Biosciences (I); Epizyme; Incyte; Karyopharm Therapeutics; Kite, a Gilead company; Numab
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Ayala Pharmaceuticals (I); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (I); Denovo Biopharma (Inst); Enterome (Inst); Genentech (Inst); Ignyta (I); Incyte (Inst); Kymera (Inst); Merck (Inst); MorphoSys/Incyte (Inst); Nanjing (Inst); Portola Pharmaceuticals (Inst); Portola Pharmaceuticals/Alexion Pharmaceuticals (Inst); Viracta Therapeutics (Inst)